Evidence map›Paper›PMID 41396304›Full record

ReviewClinical research in cardiology : official journal of the German Cardiac Society2025

Association between skin autofluorescence and all-cause mortality, cardiovascular mortality and cardiovascular disease: a systematic review and meta-analysis.

Carlos Pascual-Morena, Maribel Lucerón-Lucas-Torres, Irene Martínez-García, Eva Rodríguez-Gutiérrez, Valeria Reynolds-Cortez, Silvana Patiño-Cardona

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical research in cardiology : official journal of the German Cardiac Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carlos Pascual-MorenaHealth and Social Research Center, University of Castilla-La Mancha, 16071, Cuenca, Spain.ORCID http://orcid.org/0000-0003-1154-8752
Maribel Lucerón-Lucas-TorresHealth and Social Research Center, University of Castilla-La Mancha, 16071, Cuenca, Spain.ORCID http://orcid.org/0000-0002-7944-1065
Irene Martínez-GarcíaFaculty of Nursing, University of Castilla-La Mancha, 02006, Albacete, Spain. irene.mgarcia@uclm.es.ORCID http://orcid.org/0000-0001-7835-6953
Eva Rodríguez-GutiérrezHealth and Social Research Center, University of Castilla-La Mancha, 16071, Cuenca, Spain.ORCID http://orcid.org/0000-0001-6907-7872
Valeria Reynolds-CortezHealth and Social Research Center, University of Castilla-La Mancha, 16071, Cuenca, Spain.ORCID http://orcid.org/0000-0001-6140-0073
Silvana Patiño-CardonaHealth and Social Research Center, University of Castilla-La Mancha, 16071, Cuenca, Spain.ORCID http://orcid.org/0009-0001-3470-1724

Funding

Ministerio de Ciencia, Innovación y Universidades FPU21/06866
6 · The paper itself

Abstract

backgroundSkin autofluorescence (SAF) is a biomarker of tissue accumulation of advanced glycation end-products, which increase the risk of cardiovascular disease (CVD) and mortality, particularly among individuals with chronic kidney disease (CKD) or diabetes mellitus (DM).

objectiveThe aim was to summarise existing evidence and estimate the association between SAF and all-cause mortality, cardiovascular mortality and CVD.

methodsA search of Medline, Scopus, Web of Science and the Cochrane Library was conducted from inception to June 2025. Observational studies estimating the association between SAF and all-cause mortality, cardiovascular mortality and CVD were included. Meta-analyses of these associations were performed by categorising SAF (high vs. low) and by 1 arbitrary unit (AU) increment of SAF, expressed as hazard ratio (HR) or odds ratio (OR) and their 95% confidence intervals.

resultsThirty-two studies were included in the systematic review. Elevated SAF was associated with an increased risk of all-cause mortality, cardiovascular mortality and CVD. Per 1 AU increase, an HR of 1.51 (1.35, 1.69) was obtained for all-cause mortality, an HR of 1.48 (1.16, 1.90) for cardiovascular mortality and an HR of 1.25 (1.13, 1.38) for CVD. However, estimates with OR tended to be higher. Finally, the results were similar in CKD and DM.

conclusionsSAF is a strong predictor of CVD and mortality in general, and in CKD and DM in particular. Integrating SAF measurement into clinical practice could help clinicians implement early and intensive interventions to prevent associated morbidity and mortality, although clinical trials are needed to evaluate its effectiveness.

Indexed as

Cardiovascular riskChronic kidney diseaseDiabetes mellitusEpidemiologyMortalityPrognosisReviewSkin autofluorescence

Identifiers

PMID41396304

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.